thanks to alphapuppy and to his wife, I bet MRK did similar analysis, and with more inside info of say blinded data upto the date Duffy left, MRK could have come up with an even better PFS/OS numbers. What we should note is the JTM paper data what AP employed is only upto 2017 blinded data and that is giving us 26months as opposed to the 23.6months that the JTM paper reported. So, longer we wait, the data gets better as it matures more. We all should watch LL's June 2019 video more often, that every time you watch it, you learn more. She says there are 3 dozens of Brads who are 15+ yrs OS. And is predicting methylated group should get the approval at the least as the cure rate is 50+% there. At the 27th min mark, she says 3yr OS survival is 28% as opposed to the norm of 3 or 5% about 20yrs ago. She is done with the DcVaxL trial with the conviction that immunotherapy works and is ready to moving onto combo trials to get similar cure rate for unmethylated or proneural patients employing Keytruda or DcVaxL one of them I am not sure which one as adjuvant but she thinks DcVaxL is essential to the combo. Big times are ahead for us tryn2, cheers!
News 
Market Data 
Discover 
